Parnell Pharmaceuticals (CE)【PARNF】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.082

買値

0.00

売値

0.00

出来高

0.00 日の範囲 0.00

0.000001 52 週間の範囲 0.35

時価総額

9.871M

前日終値

0.082

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

34,392

発行済株式数

120,377,529

配当利回り

PER

-1.68

1 株当たり利益 (EPS)

-0.05

歳入

35.43M

純利益

-5.74M

Parnell (OTC: PARNF) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal and human health solutions. Parnell is a technology and clinical science leader in dairy reproduction, marketing its proprietary brands estroPLAN and GONAbreed... Parnell (OTC: PARNF) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal and human health solutions. Parnell is a technology and clinical science leader in dairy reproduction, marketing its proprietary brands estroPLAN and GONAbreed via its dedicated sales force and digital technology mySYNCH in the USA and Australia-New Zealand, and via distributors in other markets. Parnell has a rapidly growing contract manufacturing business supplying industry majors with specialized sterile injectable products. In companion animal, Parnell manufactures and markets its proprietary canine osteoarthritis brands Zydax and Glyde. For more information on the company and its products, please visit www.parnell.com. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.parnell.com

本社

Sydney, New South Wales, Aus

設立

Parnell Pharmaceuticals Holdings Ltd (CE) is listed in the Pharmaceutical Preparations sector of the その他OTC with ticker PARNF. The last closing price for Parnell Pharmaceuticals (CE) was US$0.08. Over the last year, Parnell Pharmaceuticals (CE) shares have traded in a share price range of US$ 0.000001 to US$ 0.35.

Parnell Pharmaceuticals (CE) currently has 120,377,529 shares in issue. The market capitalisation of Parnell Pharmaceuticals (CE) is US$9.87 million. Parnell Pharmaceuticals (CE) has a price to earnings ratio (PE ratio) of -1.68.

Parnell Pharmaceuticals Holdings Ltd Files Form 25, Voluntarily Delisting Its Shares From NASDAQ

OVERLAND PARK, Kan., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

Parnell Pharmaceuticals Holdings Ltd Announces Intention To Move From the NASDAQ OMX Global Market and Expects To Move To the...

OVERLAND PARK, Kan., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

Parnell Pharmaceuticals Holdings Ltd Announces $20 Million Secured Term Loan Facility

OVERLAND PARK, Kan., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...

Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Nine-Month Period Ended September 30, 2016

OVERLAND PARK, Kansas, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

Parnell to Report Financial Results for the Nine Months Ended September 30, 2016 on November 2, 2016

OVERLAND PARK, Kan., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...

Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2016

OVERLAND PARK, Kan., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

Parnell to Report Financial Results for the Six Months Ended June 30, 2016 on August 4, 2016

OVERLAND PARK, Kan., July 26, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd. (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and...

Parnell Pharmaceuticals Holdings Ltd Announces Contract Manufacturing Agreement with Merial

OVERLAND PARK, Kan., May 31, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

Parnell Pharmaceuticals Holdings Ltd Announces Pricing of an Underwritten Public Offering of Common Stock

OVERLAND PARK, Kan., May 12, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (NASDAQ:PARN), a fully integrated, commercial-stage pharmaceutical company focused on developing...

Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Update

Parnell continues to grow rapidly with revenue increasing 43% for the three months ended March 31, 2016OVERLAND PARK, Kan., April 22, 2016 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0.032	64	0.05	0.35	0.05	34392	0.06693432	CS
12	0.032	64	0.05	0.35	0.05	34392	0.06693432	CS
26	0.0819	81900	0.0001	0.35	1.0E-6	21135	0.06535084	CS
52	0.081999	8199900	1.0E-6	0.35	1.0E-6	13691	0.06305566	CS
156	0.0818	40900	0.0002	0.35	1.0E-6	12906	0.01721487	CS
260	-0.058	-41.4285714286	0.14	0.89	1.0E-6	12374	0.21407977	CS

PARNF - Frequently Asked Questions (FAQ)

What is the current Parnell Pharmaceuticals (CE) share price?

The current share price of Parnell Pharmaceuticals (CE) is US$ 0.082

How many Parnell Pharmaceuticals (CE) shares are in issue?

Parnell Pharmaceuticals (CE) has 120,377,529 shares in issue

What is the market cap of Parnell Pharmaceuticals (CE)?

The market capitalisation of Parnell Pharmaceuticals (CE) is USD 9.87M

What is the 1 year trading range for Parnell Pharmaceuticals (CE) share price?

Parnell Pharmaceuticals (CE) has traded in the range of US$ 0.000001 to US$ 0.35 during the past year

What is the PE ratio of Parnell Pharmaceuticals (CE)?

The price to earnings ratio of Parnell Pharmaceuticals (CE) is -1.68

What is the cash to sales ratio of Parnell Pharmaceuticals (CE)?

The cash to sales ratio of Parnell Pharmaceuticals (CE) is 0.27

What is the reporting currency for Parnell Pharmaceuticals (CE)?

Parnell Pharmaceuticals (CE) reports financial results in AUD

What is the latest annual turnover for Parnell Pharmaceuticals (CE)?

The latest annual turnover of Parnell Pharmaceuticals (CE) is AUD 35.43M

What is the latest annual profit for Parnell Pharmaceuticals (CE)?

The latest annual profit of Parnell Pharmaceuticals (CE) is AUD -5.74M

What is the registered address of Parnell Pharmaceuticals (CE)?

The registered address for Parnell Pharmaceuticals (CE) is UNIT 4 CENTURY ESTATE, 476 GARDENERS ROAD, ALEXANDRIA, SYDNEY, NEW SOUTH WALES, 2015

What is the Parnell Pharmaceuticals (CE) website address?

The website address for Parnell Pharmaceuticals (CE) is www.parnell.com

Which industry sector does Parnell Pharmaceuticals (CE) operate in?

Parnell Pharmaceuticals (CE) operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
DTEMFDitem Explorations (CE)	US$ 0.01 (999,900.00%)	1,000
RRMLFRoss River Minerals Inc (CE)	US$ 0.0089 (889,900.00%)	9.95k
FGHFFForte Group Holdings Inc (PK)	US$ 0.3833 (29,384.62%)	432
PRMDPrimeMD Inc (CE)	US$ 0.0002 (19,900.00%)	100
SDCCQSmileDirectClub Inc (CE)	US$ 0.0002 (19,900.00%)	392.07k
CDJMCarnegie Development Inc (CE)	US$ 0.000001 (-100.00%)	2.58k
RAHGFRoan Holdings Group Company Ltd (CE)	US$ 0.000001 (-99.99%)	200
UBMRFUrbanimmersive Inc (CE)	US$ 0.000001 (-99.97%)	1.5k
UNDRUnderSea Recovery Corporation (CE)	US$ 0.000001 (-99.90%)	55k
EICCFE Automotive Inc (CE)	US$ 0.0001 (-99.88%)	5.67k
PHILPHI Group Inc (PK)	US$ 0.0005 (0.00%)	562.38M
GRLFGreen Leaf Innovations Inc (PK)	US$ 0.0001 (0.00%)	284.6M
RDARRaadr Inc (PK)	US$ 0.0016 (-5.88%)	170.08M
HMBLHUMBL Inc (PK)	US$ 0.00085 (6.25%)	153.18M
CGACCode Green Apparel Corp (PK)	US$ 0.0004 (-11.11%)	113.22M